Morphologic flassifications of myelodysplastic syndromes: French–American–British (FAB) and World Health Organization (WHO)

Myelodysplastic Syndromes: Clinical and Biological Advances

Volumn , Issue , 2005, Pages 33-62

  Richard, D Brunning ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928617745     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545269.003     Document Type: Chapter

References (100)

1. Bennett, J. M., Catovsky, D., Daniel, M.T. et al. (1976). Proposals for the classification of the acute leukaemias. Br. J. Haematol., 33, 451–8.
2. Bennett, J. M., Catovsky, D., Daniel, M.T. et al. (1982). Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol., 51, 189–99.
3. Brunning, R. D., Bennett, J. M., Flandrin, G. et al. (2001). Myelodysplastic syndromes and acute myeloid leukaemias. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed. E. S. Jaffe, N. L. Harris, H. Stein and J. W. Vardiman. Lyon: IARC Press, pp. 61–106.
4. Brunning, R. D. andMcKenna, R.W. (1994).Myelodysplastic syndromes. In Tumors of the Bone Marrow, Atlas of Tumor Pathology, third series, fascicle 9, ed. J. Rosai. Washington, DC: Armed Forces Institute of Pathology, pp. 143–94.
5. Phelan, J. T. II, Kouides, P. A., and Bennett, J. M. (2002).Myelodysplastic syndromes: historical aspects and classification. New York: Marcel Dekker, pp. 1–14.
6. Balduini, C. L., Guarnone, R., Pecci, A., Centenara, E., and Ascari, E. (1998). Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes. Leukemia, 12, 1655–6 (letter).
7. Michels, S., Chan, W., Jakubowski, D., andVogler, R. (1990).Unclassifiablemyelodysplastic syndrome: a study of sixteen cases with a proposal for a new subtype. Lab. Invest., 62, 67 (abstract).
8. Rosati, S., Mick, R., Xu, F. et al. (1996). Refractory cytopenia with multilineage dysplasia: further characterization of an “unclassifiable” myelodysplastic syndrome. Leukemia, 10, 20–6.
9. Boultwood, J., Lewis, S., andWainscoat, J. S. (1994). The 5q− syndrome. Blood, 84, 3253–60.
10. Gregg, X. T., Reddy, V., and Prchal, J. T. (2002) Copper deficiency masquerading as myelodysplastic syndrome. Blood, 100, 1493–5.
11. Irving, J. A., Mattman, A., Lockitch, G., and Farrell, K. (2003). Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. C.M.A.J., 169, 129–31.
12. Rosati, S., Anastasi, J., and Vardiman, J. (1996). Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin. Hematol., 33, 111–26.
13. Westhoff, D. D., Samaha, R. J., and Barnes, A. Jr. (1975). Arsenic intoxication as a cause of megaloblastic anemia. Blood, 45, 241–6.
14. Baurmann, H., Schwatz, T. F., Oertel, J. et al. (1992). Acute parvovirus infection mimickingmyelodysplastic syndrome of the bone marrow. Ann.Hematol., 64, 43–5.
15. Schmitz, L. L., McClure, J. S., Litz, C. E. et al. (1994).Morphologic and quantitative changes in blood and marrow cells following growth factor therapy. Am. J. Clin. Pathol., 101, 67–75.
16. Katoutsi, V., Kohlmeyer, U., Maschek, H. et al. (1994). Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and thosewithmyelodysplastic syndromes and infectious disease.Am. J. Clin.Pathol., 101, 123.
17. Treacy, M., Lai, L., Costello, C., and Clark, A. (1987). Peripheral blood and bone marrow abnormalities in patients with HIV related disease. Br. J. Haematol., 65, 289–94.
18. Delacetaz, F., Schmidt, P. M., Piguet, D. et al. (1987). Histopathology of myelodysplastic syndromes. Am. J. Clin. Pathol., 87, 180–6.
19. Germing, U., Gattermann, N., Aivado, M. et al. (2000). Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br. J. Haematol., 108, 724–8.
20. Greenberg, P., Cox, C., Le Beau, M. M. et al. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079–88.
21. Bernstein, S. H., Brunetto, V. L., and Davey, F. R. (1996). Acute myeloid leukemiatype chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndromes as defined by French–American–British criteria: a Cancer and Leukemia Group B study. J. Clin. Oncol., 14, 2486–94.
22. Estey, E., Pierce, S., Kantarjian, H. et al. (1993). Treatment of myelodysplastic syndromesb with AML-type chemotherapy. Leuk. Lymphoma, 11 (suppl. 2), 59–63.
23. Estey, E., Thall, P., Beran, M. et al. (1997). Effects of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation or acutemyeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood, 90, 2969–77.
24. Vardiman, J.W., Harris, N. L., and Brunning, R. D. (2002). TheWorld Health Organization (WHO) classification of myeloid neoplasms. Blood, 100, 2292–302.
25. Menke, D. M., Colon-Otero, G., Cockerill, K. J. et al. (1992). Refractory thrombocytopenia: amyelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am. J. Clin. Pathol., 98, 502–10.
26. Tricot, G., Criel, A., and Verwilghen, R. L. (1982). Thrombocytopenia as presenting symptom of preleukaemia in three patients. Scand. J. Haematol., 28, 243–50.
27. Steensma, D. P., DeWald, G. W., Hodnefield, J. M. et al. (2003). Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? Leuk. Res., 27, 235–42.
28. Olney, H. J. and Le Beau, M. M. (2002). Cytogenetics and molecular biology of myelodysplastic syndromes. In The Myelodysplastic Syndromes, Pathobiology and Clinical Management, ed. J. M. Bennett. New York: Marcel Dekker, pp. 89–119.
29. Rigolin, G. M., Bigoni, R., Milani, R. et al. (2001). Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia, 15, 1841–7.
30. Cermak, J., Michalova, K., Brezinova, J. et al. (2003). A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q− syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk. Res., 27, 221–9.
31. Giagounidis, A. N. N., Germing, U., Haase, S. et al. (2004). Clinical, morphological, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia, 18, 113–19.
32. Lai, F., Godley, L. A., Joslin, J. et al. (2001). Transcript map and comparative analysis of the 1.5 Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del (5q). Genomics, 71, 235–45.
33. Kurtin, P. J., Dewald, G. W., Shields, D. J., and Hanson, C. A. (1996). Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am. J. Clin. Pathol., 106, 680–8.
34. Lai, J. L., Preudhomme, C., Zandecki, M. et al. (1995). Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia, 9, 370–81.
35. Sankar, M., Tanaka, K., Kumaravel, T. S. et al. (1998). Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality. Leukemia, 12, 510–16.
36. Ellis, M., Ravid, M., and Lishner, M. (1993). A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leuk. Lymphoma, 11, 9–13.
37. Godley, L. A. and Larson, R. A. (2002). The syndrome of therapy related myelodysplasia and myeloid leukemia. In The Myelodysplastic Syndromes, Pathobiology and Clinical Management, ed. J. M. Bennett. New York: Marcel Dekker, pp. 139–76.
38. Latagliata, R., Petti, M. C., Fenu, S. et al. (2002). Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood, 99, 822–4.
39. Le Beau, M. M., Albain, K. S., Larson, R. A. et al. (1986). Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J. Clin. Oncol., 4, 325–45.
40. Merlat, A., Lai, J. L., Sterkers, Y. et al. (1999). Therapy-related myelodysplastic syndromeand acutemyeloid leukemiawith 17p deletion.Areport on 25 cases. Leukemia, 13, 250–7.
41. Michels, S.D., McKenna, R.W., Arthur, D. C., and Brunning, R.D. (1985). Therapyrelated acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood, 65, 1364–72.
42. Pedersen-Bjergaard, J., Andersen, M. K., Christiansen, D. H., and Nerlov, C. (2002). Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood, 99, 1909–12.
43. Pedersen-Bjergaard, J., Phillip, P., Larsen, S. O. et al. (1993). Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant disease in the Copenhagen series. Leukemia, 7, 1975–86.
44. Pedersen-Bjergaard, J. (2005). Insights into leukemogenesis from therapy-related leukemia. N. Engl. J. Med., 352, 1591–4.
45. Quesnel, B., Kantarjian, H., Pedersen-Bjergaard, J. et al. (1993). Therapy-related acute myeloid leukemia with t(8;21), Inv(16) and t(8;16): a report on 25 cases and review of the literature. J. Clin. Oncol., 11, 2370–9.
46. Pui, C. H., Relling, M. V., Rivera, G. K. et al. (1995). Epipodophyllotoxin-related acute myeloid leukemia; a study of 35 cases. Leukemia, 9, 1990–6.
47. Rowley, J. D. and Olney, H. J. (2002). International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related leukemia and myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer, 33, 331–45.
48. Secker-Walker, L. M., Moorman, A. V., Bain, B. J., and Mehta, A. B. (1998). Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities: EU concerted action 11q23 workshop. Leukemia, 12, 840–4.
49. Lobe, I., Rigal-Huguet, F., Vekhoff, A. et al. (2003). Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia, 17, 1600–4.
50. Rios, A., Canizo, M. C., Sanz, A. et al. (1990). Bone marrowbiopsy inmyelodysplastic syndromes: morphologic characteristics and contribution to the study of prognostic factors. Br. J. Haematol., 75, 26–33.
51. Tomonga, M. and Nagai, K. (2002). Hypocellular myelodysplastic syndromes and acutemyeloid leukemia: relationship to aplastic anemia. In TheMyelodysplastic Syndromes, Pathobiology and ClinicalManagement, ed. J. M. Bennett. New York:Marcel Dekker, pp. 121–38.
52. Tricot, G., DeWolf-Peeters, C., Vlietinck, R., and Verwilghen, R. L. (1984). Bone marrow histology in myelodysplastic syndromes II. Prognostic value of abnormal localization of immature precursors in MDS. Br. J. Haematol., 58, 217–25.
53. Lambertenghi-Deliliers, G., Annaloro, C., Oriani, A., and Soligo, D. (1992). Myelodysplastic syndrome associated with bone marrow fibrosis. Leuk. Lymphoma, 8, 51–5.
54. Maschek, H., Georgii, A., Kaloutsi, V. et al. (1992). Myelofibrosis in primary myelodysplastic syndromes: a retrospective analysis of 352 patients. Eur. J.Haematol., 48, 208–14.
55. Steensma, D. P., Hanson, C. A., Letendre, L., and Tefferi, A. (2001). Myelodysplasia with fibrosis: a distinct entity? Leuk. Res., 25, 829–38.
56. Sultan, C., Sigaux, F., Imbert, M., and Reyes, F. (1981). Acute myelodysplasia with
57. myelofibrosis: a report of eight cases. Br. J. Haematol., 49, 11–16
58. Tuzuner, N., Cox, C., Rowe, J. M. et al. (1995). Hypocellular myelodysplastic syndromes (MDS): new proposals. Br. J. Haematol., 91, 612–17.
59. Yoshida, Y., Oguma, S., Uchino, H., and Maekawa, T. (1988). Refractory myelodysplastic anaemias with hypocellular bone marrow. J. Clin. Pathol., 41, 763.
60. Maschek, H., Kaloutsi, V., Rodriguez-Kaiser, M. et al. (1993).Hypoplasticmyelodysplastic syndrome: incidence, morphology, cytogenetics and prognosis. Ann. Hematol., 66, 117–22.
61. Orazi, A., Albiter, M., Heerema, N. A. et al. (1997). Hypoplastic myelodysplastic syndrome can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am. J. Clin. Pathol., 107, 268–74.
62. Barrett, J., Saunthararajah, Y., and Molldrem, J. (2000). Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin. Hematol., 37, 15–29.
63. Group Franc¸ais de Cytog´enetiqueH´ematologique (1991). Chronicmyelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet. Cytogenet, 55, 57–65.
64. Krsnik, I., Srivastava, P. C., and Galton, D. A. G. (1992). Chronic myelomonocytic leukaemia and atypical chronic myeloid leukaemia. In Myelodysplastic Syndromes, ed. F. Schmalzl and G. J. Multi. New York: Springer-Verlag, pp. 131–9.
65. Nossinger, T., Reisner, R., Gruner, H. et al. (2000). Dysplastic versus proliferative CMML – a retrospective analysis of 91 patient from a single institution. Leuk. Res., 25, 741–7.
66. Shepherd, P. C., Ganesan, T. S., and Galton, D. A. (1987). Haematological classification of the chronic myeloid leukaemias. Bailli`ere’s Clin. Haematol., 1, 887–906.
67. Vardiman, J. W. (2001). Myelodysplastic/myeloproliferative disease: introduction. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, ed. E. S. Jaffe, N. L. Harris, H. Stein, and J.W. Vardiman. Lyon: IARC Press, pp. 47–48.
68. Germing, U., Gattermann, N., Minning, H. et al. (1998).Problems in the classification of CMML – dysplastic versus proliferative type. Leuk. Res., 22, 871–8.
69. Steensma, D. P., Tefferi, A., and Li, C. Y. (2003). Splenic histopathological variants in chronic myelomonocytic leukemia: reinforcement of the heterogeneity of the syndrome. Leuk. Res., 27, 775–82.
70. Vardiman, J.W. (2003).Myelodysplastic syndromes, chronicmyeloproliferative diseases, andmyelodysplastic/myeloproliferative diseases. Semin.Diag. Pathol., 20, 154– 79.
71. Bennett, J. M., Catovsky, D., Daniel, M. T. et al. (1994). The chronic myeloid leukemias: guidelines for distinguishing the chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemias. Br. J. Haematol., 87, 746–54.
72. Greenberg, P., Anderson, J., de Witte, T. et al. (2000). Problematic WHO reclassification of myelodysplastic syndromes. J. Clin. Oncol., 18, 3447–9.
73. Chen, T.-C., Chou, J.-M., Ketterling, R. P. et al. (2003).Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases withmyelodysplasia. Am. J. Clin. Pathol., 120, 874–81.
74. Side, L. E., Emanuel, P. D., Taylor, B. et al. (1998). Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood, 92, 267–72.
75. Niemeyer, C. M., Fenu, S., Hasle, H. et al. (1998). Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood, 91, 365–7.
76. Hasle, H. and Niemeyer, C. (2002). Myelodysplastic syndrome and juvenile myelomonocytic leukemia in children. In The Myelodysplastic Syndromes, Pathobiology and Clinical Management, ed. J. M. Bennett. New York: Marcel Dekker, pp. 299–344.
77. Hasle, H., Niemeyer, C. M., Chessells, J. M. et al. (2003). A pediatric approach to the WHO classification of yelodysplastic and myeloproliferative diseases. Leukemia, 17, 277–82.
78. Gurbuxani, S., Vyas, P., and Crispino, J. D. (2004). Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood, 103, 399–406.
79. Hasle, H., Clemmensen, I. H., and Mikkelsen, M. (2000). Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet, 355, 165–9.
80. Lange, B. J., Kobrinsky, N., Barnard, D. R. et al. (1998). Distinct demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children’s Cancer StudyGroup Studies 2861 and 2891. Blood, 91, 608–15.
81. Lange, B. (2000). The management of neoplastic disorders of haematopoiesis in children with Down’s syndrome. Br. J. Haematol., 110, 512–24.
82. Ma, S. K., Wan, T. S. K., Chan, G. C. F. et al. (2001). Relationship between transient abnormalmyelopoiesis and acute megakaryoblastic leukaemia in Down’s syndrome. Br. J. Haematol., 112, 824–5.
83. Mundschau, G., Gurbuxani, S., Gamis, A. S. et al. (2003). Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood, 101, 4298–300.
84. Zipursky, A. (2003). Transient leukaemia – a benign form of leukaemia in newborn infants. Br. J. Haematol., 120, 930–8.
85. Hitzler, J. K., Cheung, J., Li, Y. et al. (2003). GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 101, 4301–4.
86. Rainis, L., Bercovich, D., Strehl, S. et al. (2003). Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood, 102, 981–6.
87. Wechsler, J., Greene, M., McDevitt, M. et al. (2002). Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat. Genet., 32, 148–52.
88. Heaney, M. L. and Golde, D.W. (1999).Myelodysplasia. N. Engl. J. Med., 340, 1649– 60.
89. Steensma, D. P. and Tefferi, A. (2003). The myelodysplastic syndrome(s): a perspective and review highlighting current ontroversies. Leuk. Res., 27, 95–120
90. Brunning, R. D. (2003). MDS – new classification, new problem? Leuk. Res., 27, 567–9.
91. Cobo, F., Quinto, L. L., Rozman, M. et al. (2003). Analysis of 178 myelodysplastic syndrome patients: validation of the World Health Organization classification and the International Prognostic Scoring System. Leuk. Res., 27, S18–19.
92. Germing, U., Gattermann, N., Strupp, C. et al. (2000). Validation of the WHO proposals for a new classification of primarymyelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res., 24, 983–92.
93. Howe, R., Porwit-MacDonald, A., Wanat, R. et al. (2004). The WHO classification of MDS does make a difference. Blood, 103, 3265–70.
94. Lee, J. H., Lee, J. H., Shin, Y. R. et al. (2003). Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia, 17, 305–13.
95. Nosslinger, T., Reisner, R., Koller, E. et al. (2002). Myelodysplastic syndromes from French–American–British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood, 98, 2935–41.
96. Strupp, C., Gattermann, N., Giagounidis, A. et al. (2003). Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk. Res., 27, 397–404.
97. Head, D. R. (1996). Revised classification of acute myeloid leukemia. Leukemia, 10, 1826–31.
98. Willman, C. L. (1998). Molecular genetic features of myelodysplastic syndromes. Leukemia, 12, S2–6.
99. Wattel, E., DeBotton, S., Luc Lai, J. et al. (1997). Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of longterm survivors and outcome of partial responders. Br. J. Haematol., 98, 983–91.
100. DeWitte, T., Sucio, S., Peetermans, M. et al. (1995). Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia following MDS of more than 8 months duration. A pilot study by the Leukemia Committee of the EORTC. Leukemia, 9, 1805.